US Patent

US7842714 — Ketorolac tromethamine compositions for treating ocular pain

Composition of Matter · Assigned to Allergan Inc · Expires 2029-08-15 · 3y remaining

Vulnerability score 15/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects an aqueous ophthalmic solution containing ketorolac tromethamine and carboxymethyl cellulose for treating ocular pain.

USPTO Abstract

The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Drugs covered by this patent

Patent Metadata

Patent number
US7842714
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-08-15
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.